Roberto Rached currently serves as the Director of Launch Medical within Global Medical Affairs at Novartis, specializing in Hematology. In this pivotal role, he is responsible for executing comprehensive medical affairs launch strategies for innovative hematology products. His expertise lies in transforming traditional approaches through...
Roberto Rached currently serves as the Director of Launch Medical within Global Medical Affairs at Novartis, specializing in Hematology. In this pivotal role, he is responsible for executing comprehensive medical affairs launch strategies for innovative hematology products. His expertise lies in transforming traditional approaches through innovative partnerships and integrated evidence plans that enhance patient care and drive healthcare innovation. Roberto’s strategic vision is focused on building robust relationships with key healthcare association stakeholders, ensuring that Novartis aligns its objectives with the broader goals of improving patient outcomes.
Roberto’s work involves co-developing evidence generation plans that are critical for the successful launch of hematology therapies. He collaborates closely with therapeutic area teams to design and implement medical education programs, scientific publication strategies, and the development of a Medical Expert network. His ability to navigate the complexities of the pharmaceutical industry, particularly in hematology and oncology, positions him as a thought leader in the field. With a strong foundation in clinical research and regulatory affairs, Roberto is adept at leveraging his skills to foster meaningful collaborations that advance scientific understanding and patient care.
Key projects under Roberto’s leadership include initiatives aimed at enhancing population health through targeted research and innovative partnerships with healthcare organizations. His commitment to excellence in medical affairs not only supports Novartis’s mission but also contributes to the broader healthcare landscape by ensuring that new therapies are effectively integrated into clinical practice. Through his strategic engagement with external stakeholders, Roberto is dedicated to driving innovation that ultimately leads to improved health outcomes for patients with hematologic conditions.
